May 22, 2015
Early IOP safety data are encouraging for Medidur, a treatment for posterior uveitis in phase 3 trial, pSivida announced in a press release.
At 3 months, only 4% more study eyes demonstrated elevated IOL than did fellow eyes that did not receive Medidur, the release said. Assessment data on IOP elevation to greater than 21 mm Hg were available for 105 of 129 enrolled subjects. The trial’s primary endpoint is recurrence of posterior uveitis within 1 year.